Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives

Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives

Gemma Camiña-Conforto, Laura Mateu-Arrom, Anna López-Ferrer, Lluís Puig Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainCorrespondence: Gemma Camiña-Conforto, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, Bloque A, 5a planta (secr...

Full description

Bibliographic Details
Main Authors:	Camiña-Conforto G, Mateu-Arrom L, López-Ferrer A, Puig L
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-06-01
Series:	Patient Preference and Adherence
Subjects:	psoriasis bimekizumab patient selection interleukin-17 patient compliance biological therapy
Online Access:	https://www.dovepress.com/bimekizumab-in-the-treatment-of-plaque-psoriasis-focus-on-patient-sele-peer-reviewed-fulltext-article-PPA

Similar Items

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
by: Joshua Burshtein, et al.
Published: (2024-02-01)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
by: Matteo Megna, MD, et al.
Published: (2023-08-01)

Bimekizumab: the new drug in the biologics armamentarium for psoriasis
by: Egídio Freitas, et al.
Published: (2021-06-01)

An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far
by: G Oliveira D, et al.
Published: (2021-03-01)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
by: Luigi Gargiulo, et al.
Published: (2023-08-01)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
by: Ruggiero A, et al.
Published: (2022-06-01)

Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain
by: Ricardo Ruiz-Villaverde, et al.
Published: (2024-02-01)

Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials
by: Yuanyuan Qiu, et al.
Published: (2023-12-01)

Review of bimekizumab in the treatment of psoriasis
by: Sindhuja Koppu, et al.
Published: (2022-11-01)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
by: Chiricozzi A, et al.
Published: (2019-05-01)

Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis
by: Alice B. Gottlieb, et al.
Published: (2020-08-01)

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
by: Akihiko Asahina, et al.
Published: (2023-01-01)

Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
by: Guillermo Sánchez-Rodríguez, et al.
Published: (2023-06-01)

The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy
by: Georgios Kokolakis, et al.
Published: (2022-12-01)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01)

Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis
by: Kivitz A, et al.
Published: (2023-10-01)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
by: Yang EJ, et al.
Published: (2018-10-01)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
by: Talamonti M, et al.
Published: (2023-04-01)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
by: Kristian Reich, et al.
Published: (2022-03-01)

T helper type 17 in psoriasis: From basic immunology to clinical practice
by: Hsien-Yi Chiu, et al.
Published: (2012-12-01)

On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study
by: Pim Sermsaksasithorn, et al.
Published: (2022-10-01)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017-11-01)

Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
by: Luis Puig, et al.
Published: (2021-10-01)

IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa
by: Dalma Malvaso, et al.
Published: (2023-10-01)

Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis
by: April W. Armstrong, et al.
Published: (2017-04-01)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021-01-01)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017-06-01)

Genetic and Epigenetic Mechanisms of Psoriasis
by: Laura Mateu-Arrom, et al.
Published: (2023-08-01)

Secukinumab – first in class interleukin-17A inhibitor for the treatment of psoriasis
by: Kiran Godse
Published: (2017-01-01)

Immunohistochemical demonstration of interleukin-17 positivity in skin biopsy specimens of patients with chronic plaque psoriasis and its correlation with severity of psoriasis and associated metabolic syndrome and cardiovascular changes
by: Madivalara Yallappa Suparna, et al.
Published: (2022-01-01)

Clinical application of serum biomarkers for detecting and monitoring of chronic plaque psoriasis
by: Criselda Jean G. Cruz, et al.
Published: (2023-07-01)

Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study
by: Katarzyna Galica, et al.
Published: (2020-07-01)

Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management
by: Hazrat Bilal, et al.
Published: (2024-01-01)

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis
by: A. V. Samtsov, et al.
Published: (2018-01-01)

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
by: Gianluca Avallone, et al.
Published: (2023-02-01)

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
by: Marie-Astrid Boutet, et al.
Published: (2018-02-01)

Higher IL-9 Level is Associated with Psoriasis Vulgaris Complicated by Metabolic Syndrome
by: Yan L, et al.
Published: (2023-08-01)

A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis
by: Anchala Parthasaradhi, et al.
Published: (2017-01-01)

New therapeutic targets for the management of moderate-severe psoriasis
by: José C. Ruiz-Carrascosa, et al.
Published: (2022-04-01)

The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
by: Nyholm N, et al.
Published: (2023-07-01)